Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. (Record no. 7767441)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01474 a2200421 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250513042927.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 199506s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 0009-9236 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1016/0009-9236(95)90035-7 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Dingemanse, J |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 19950630 |
| 245 00 - TITLE STATEMENT | |
| Title | Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | Clinical pharmacology and therapeutics |
| Date of publication, distribution, etc. | May 1995 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 508-17 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Administration, Oral |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Adult |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Benzophenones |
| General subdivision | adverse effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Catechol O-Methyltransferase Inhibitors |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Dose-Response Relationship, Drug |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Double-Blind Method |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Half-Life |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Intestinal Absorption |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Male |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Nitrophenols |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Tolcapone |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Jorga, K M |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Schmitt, M |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Gieschke, R |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Fotteler, B |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Zürcher, G |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Da Prada, M |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | van Brummelen, P |
| 773 0# - HOST ITEM ENTRY | |
| Title | Clinical pharmacology and therapeutics |
| Related parts | vol. 57 |
| -- | no. 5 |
| -- | p. 508-17 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1016/0009-9236(95)90035-7">https://doi.org/10.1016/0009-9236(95)90035-7</a> |
| Public note | Available from publisher's website |
No items available.